Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Vaccinex Inc released Revenue of $0.85 million, in the fiscal span ending December 31 2022
VCNX reported fourth quarter of 2022 operating shortfall of $-7.703 million
Published Apr 02 2023
CSIMarket Team / CSIMarket.com
For the fourth quarter of 2022 Vaccinex Inc realized net shortfall of $-7.643 million, higher than $-4.631 million a year ago.
Furthermore, the Vaccinex Inc noted also a shortfall of $-22.38 million and for the fiscal period 2021, revenue of $0.90 million.
Major Pharmaceutical Preparations Vaccinex Inc has decreased it's shortfall per share to $-0.78 from $-1.54 in the prior fiscal year, while revenue surged by 44 % from $0.63 million a year prior.
Vaccinex Inc is expected to report next financial earnings on May 15, 2023.
Other VCNX's news
Vaccinex*s Financial Moves Pave the Way for Innovative Alzheimer*s and Cancer Therapies
Vaccinex Expands Access to ActivMAb Antigen Virus Technology Through Eight New Agreements
Vaccinex, Inc. Reverse Stock Split: A Boost or a Bust for Investors?
Vaccinex Granted Nasdaq Extension Amidst Strong Q3 2023 Performance, Boosting Investor Confidence
Vaccinex Inc Announces Troubling Operating Shortfall and Revenue Delay in Q2 2023 Financial Results
Vaccinex Inc released Revenue of $0.85 million, in the fiscal span ending December 31 2022
The company released operating deficit of $-5.401 million, in the most recent fiscal period
Observing the first quarter of 2022 numbers, VCNXs* made top-line remained unaltered
Other VCNX's news
Vaccinex*s Financial Moves Pave the Way for Innovative Alzheimer*s and Cancer Therapies
Vaccinex Expands Access to ActivMAb Antigen Virus Technology Through Eight New Agreements
Vaccinex, Inc. Reverse Stock Split: A Boost or a Bust for Investors?
Vaccinex Granted Nasdaq Extension Amidst Strong Q3 2023 Performance, Boosting Investor Confidence
Vaccinex Inc Announces Troubling Operating Shortfall and Revenue Delay in Q2 2023 Financial Results
Vaccinex Inc released Revenue of $0.85 million, in the fiscal span ending December 31 2022
The company released operating deficit of $-5.401 million, in the most recent fiscal period
Observing the first quarter of 2022 numbers, VCNXs* made top-line remained unaltered